Olivia Vizier

empowered

New Landscape for Controlling Obesity and Lowering Incidence of Related Diseases with Dr. Steffen-Sebastian Bolz Aphaia Pharma

Dr. Steffen-Sebastian Bolz, Chief Scientific Officer of Swiss-based Aphaia Pharma, shines a light on the excitement around weight loss drugs due to the discovery that GLP-1 agonists and points out the shift in the perception of obesity as a root cause of various health issues.

New Landscape for Controlling Obesity and Lowering Incidence of Related Diseases with Dr. Steffen-Sebastian Bolz Aphaia Pharma Read More »

Cell Gene Podcast

Developing an mRNA Therapy for DMD with Elixirgen Therapeutics’ Aki Ko on Apple Podcasts

Elixirgen Therapeutics’ Aki Ko joins Erin Harris to detail the company’s Bobcat mRNA therapeutic and how it differs from traditional exon-skipping drugs and AAV-microdystrophin in treating DMD. Regarding delivery, Ko explains the advantage of the mRNA approach over the AAV approach.

Developing an mRNA Therapy for DMD with Elixirgen Therapeutics’ Aki Ko on Apple Podcasts Read More »

Biotech TV

In humanized mouse models, Tessera is demonstrating LNP delivery of gene writers to, and rewriting of, hematopoietic stem cells to an extent that could be curative in sickle cell disease

CEO Mike Severino describes the sickle cell data Tessera is presenting at #ASGCT2024, and highlights the company’s gene writing platform and programs more broadly.

In humanized mouse models, Tessera is demonstrating LNP delivery of gene writers to, and rewriting of, hematopoietic stem cells to an extent that could be curative in sickle cell disease Read More »

Scrip_Domain

Hibernating Squirrels And Exercise In A Pill: The Next Wave of Cardiometabolic Therapies

Aphaia Pharma, a Swiss biotech, is developing an oral glucose formulation. This aims to restore endogenous signaling mechanisms and metabolic homeostasis in people with obesity, with the goal of mimicking the metabolic effects of bypass surgery without the adverse effects. Its lead drug candidate is currently in a Phase II proof-of-concept study in individuals with

Hibernating Squirrels And Exercise In A Pill: The Next Wave of Cardiometabolic Therapies Read More »

BioProcessOnline

New Apps For AI in mRNA With Anima Biotech’s Yochi Slonim

From San Francisco’s Silicon Valley to Tel Aviv’s Silicon Wadi, software business entrepreneur Yochi Slonim made a name for himself in tech hubs around the globe. Notably, he was co-founder of billion-dollar Mercury Interactive, which HP acquired for $4.5 billion, and previous to that a leader at Tecnomatix, which sold to UGS and was acquired

New Apps For AI in mRNA With Anima Biotech’s Yochi Slonim Read More »

Biotech_Nation

How Can a Treatment Become a Vaccine??? Dr. Peter DeMuth, Chief Scientific Officer at Elicio Therapeutics

Dr. Peter DeMuth, Chief Scientific Officer of Elicio Therapeutics, discusses the revolutionary approach of detecting cancer at its earliest stages through circulating tumor DNA (ctDNA) tests. Highlighting their innovative treatment method, which aims to train the body’s immune cells to recognize and destroy cancer cells, the episode explores the potential transition from treatment to vaccine,

How Can a Treatment Become a Vaccine??? Dr. Peter DeMuth, Chief Scientific Officer at Elicio Therapeutics Read More »